GlassScriptPhysician profile
David P Jones
NPI 1265410914
$8,660.18
in general payments reported to CMS, 2019-2025
35 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $38.63 · 2021: $703 · 2022: $1,697 · 2023: $1,831 · 2024: $2,286 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,854 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,854.04 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,564.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,291.58 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $746.63 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $662.38 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $392.88 | 2022-2025 | Ibsrela |
| Celgene Corporation | $330.97 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $303.86 | 2019-2025 | |
| Pfizer INC. | $288.23 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $231.52 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $214.59 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $212.62 | 2022-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $166.31 | 2021-2022 | |
| Genzyme Corporation | $159.06 | 2023-2025 | |
| Madrigal Pharmaceuticals | $124.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Alcresta Therapeutics, INC. | $122.39 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $117.18 | 2022-2024 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $103.07 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $101.10 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $71.89 | 2021-2025 | Ocaliva |
| Celltrion USA INC. | $66.18 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $61.21 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $58.91 | 2024-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $50.62 | 2022-2023 | Linzess |
| Daiichi Sankyo INC. | $38.01 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.11 | 2022-2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $22.53 | 2022 | |
| Vivus LLC | $21.26 | 2025 | Pancreaze |
| Fresenius Kabi USA, LLC | $20.74 | 2023 | Idacio |
| Novo Nordisk INC | $17.23 | 2025 | Wegovy |
| Capsovision, INC. | $16.33 | 2023 | Capsocam Plus |
| Electromed, INC. | $15.15 | 2024 | Smartvest |
| Olympus America INC. | $14.64 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.50 | 2025 | Suflave |
| Zyla Life Sciences, INC. | $11.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,184.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.